Sign in

    David Bautz

    Senior Analyst at Zacks Small-Cap Research

    David Bautz, PhD, is a Senior Analyst at Zacks Small-Cap Research specializing in healthcare, particularly biotechnology and pharmaceutical companies. Since joining Zacks in 2014, he has covered firms such as MediciNova and Imunon, publishing detailed equity research and company reports with performance metrics including stock price targets and return analyses; for example, his forecasts on MediciNova provided comprehensive evaluations of valuation and risk. Previously, Dr. Bautz was an NRSA postdoctoral fellow investigating colorectal cancer genetics and held research roles at Human Genome Sciences before earning his PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill. While he holds a strong academic and industry research background, available records do not indicate FINRA registration or securities licenses.

    David Bautz's questions to ABEONA THERAPEUTICS (ABEO) leadership

    David Bautz's questions to ABEONA THERAPEUTICS (ABEO) leadership • Q1 2025

    Question

    David Bautz of Zacks Small-Cap Research asked for details on the billing and reimbursement workflow, including the expected time from patient treatment to payment, and questioned the specific intentions of the 30 patients who have contacted the company.

    Answer

    Chief Commercial Officer Dr. Madhav Vasanthavada explained that revenue is recognized after treatment, with payment timing on par with other cell and gene therapies, and reimbursement is secured before treatment begins. He clarified that the patient inquiries were general expressions of interest to "get in the queue" before a specific QTC was announced. CEO Dr. Vish Seshadri added this pre-authorization process explains the lead time before the first patient treatment.

    Ask Fintool Equity Research AI

    David Bautz's questions to Qualigen Therapeutics (QLGN) leadership

    David Bautz's questions to Qualigen Therapeutics (QLGN) leadership • Q1 2021

    Question

    David Bautz from Zacks Small-Cap Research asked for details on the planned COVID-19 clinical trial design, whether the ALAN drug candidate would be developed as a monotherapy or combination therapy for AML, and the current development stage and expected timeline for the RAS-F program.

    Answer

    CEO Michael Poirier explained the COVID-19 trial is planned for approximately 500 patients across multiple arms, including one with remdesivir. For ALAN, he noted that while a monotherapy would be ideal, a combination therapy is more likely given the heterogeneity of AML. Regarding the RAS-F program, he stated the company is working to select a lead candidate from about 160 compounds, with pre-IND studies expected to begin in early 2021, at which point a more detailed update will be provided.

    Ask Fintool Equity Research AI